| NCT ID | NCT07761026 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Autoimmune Neurology Alliance |
| Condition | Myasthenia Gravis (MG) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-03-19 |
| Primary Completion | 2036-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2026-03-19 with a primary completion date of 2036-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time. The main questions the registry aims to answer are: * How do symptoms, daily functioning, and quality of life change over time? * What treatments do participants use, and how are these treatments related to their symptoms and health? * What challenges do participants experience with treatment, including side effects, treatment burden, missed doses, and access to care? Participants will: * Join the registry and complete an enrollment survey (online or through a mobile app) * Complete a brief online survey about their MG approximately once a month * Provide information that can help confirm their MG diagnosis * Optionally, share their medical records with the research team This is an observational study. The registry will not assign treatments or ask participants to change their medical care. Information collected through the registry may help researchers better understand MG and improve future research and care.
Eligibility Criteria
Inclusion Criteria: * Physician-confirmed diagnosis of myasthenia gravis (MG) * Willing and legally able to provide consent * Lives in the United States Exclusion Criteria: * Unwilling or unable to provide consent or comprehend and complete questionnaires * Cognitively impaired adults/unable to comprehend or understand the consent or overall study information
Contact & Investigator
Richard J Nowak, MD, MS
STUDY CHAIR
Yale University
Frequently Asked Questions
Who can join the NCT07761026 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myasthenia Gravis (MG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07761026 currently recruiting?
Yes, NCT07761026 is actively recruiting participants. Contact the research team at support@axispatientregistry.com for enrollment information.
Where is the NCT07761026 trial being conducted?
This trial is being conducted at Framingham, United States.
Who is sponsoring the NCT07761026 clinical trial?
NCT07761026 is sponsored by Autoimmune Neurology Alliance. The principal investigator is Richard J Nowak, MD, MS at Yale University. The trial plans to enroll 1,000 participants.